To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Liver Cancer Stage IV|Gastric Cancer Stage IV|Esophageal Cancer, Stage IV|Bone and Soft Tissue Tumors|Breast Cancer Stage IV|Bladder Carcinoma Stage IV|Prostate Carcinoma Stage IV|Thyroid Cancer Stage IV|Ovarian Cancer Stage IV|Solid Tumor
Interventions: DRUG: TAEST16001
Sponsor: Zhujiang Hospital
Collaborators: Xiangxue Life Science Research Center|Guangdong Xiangxue Precision Medical Technology Co., Ltd.|Xiangxue Pharmaceutical